Every material Form 8-K Azitra, Inc. has filed with the SEC since October 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Azitra amended the Phase 1/2 trial of its ATR-04 candidate to include patients with rash caused by KRAS and MEK inhibitors and neurofibromatosis type 1 patients with MEK inhibitor-associated rash, and shortened washout periods for antibiotics and steroids. The filing says the changes broaden the potential treatment opportunities for ATR-04 and are intended to speed patient recruitment, but it gives no financial figures and no timeline for results.
Eligibility now includes patients with rash associated with KRAS and MEK inhibitors, plus NF1 patients with MEK inhibitor-associated rash.
Washout periods for antibiotics and steroids are shortened under the amendments.
Cohort 2 is expected to enroll approximately 24 patients receiving once-daily treatment for 28 days, following the safety review committee's recommendation to proceed.
Azitra cites about 85,000 U.S. patients a year on KRAS or MEK inhibitors, compared with about 220,000 on EGFR inhibitors.
Azitra said it will not sell shares under its at-the-market offering program with A.G.P./Alliance Global Partners for the foreseeable future. From September 28 through October 26, 2026, the company sold 1,000 shares for approximately $126 in gross proceeds, and it may resume sales or pursue other financing at any time. The same day, it released ex vivo study results for its ATR-COSF cosmetic candidate and said first-in-human initial results are expected by year end.
From September 28 through October 26, 2026, Azitra sold 1,000 shares under the ATM Program for aggregate gross proceeds of approximately $126.
On October 26, 2026, the company decided not to use the ATM Program for the foreseeable future, citing capital resources, upcoming operational milestones, the recent trading price and dilution to existing stockholders.
The company may resume ATM sales or pursue other financing transactions at any time and gave no assurance as to whether or when it will do so.
The same-day press release reported ex vivo data for ATR-COSF; detailed data are to be presented at BIO-Europe in Cologne on November 10, 2026, and first-in-human initial data are expected by year end.
Azitra said its safety review committee recommended that the Phase 1/2 trial of ATR04-484 for EGFR inhibitor-associated skin rash may proceed to Cohort 2, allowing enrollment and dosing to begin in that cohort. The filing contains no financial results, and the update concerns clinical progress only, based on a safety review of six patients from Cohort 1.
Safety review committee recommended proceeding to Cohort 2 after reviewing safety data from six patients in Cohort 1 (seven patients received a single 4g application).
Cohort 2 is expected to enroll approximately 24 patients receiving a 4g application once daily for 28 days.
The study is being conducted at six clinical sites, including MD Anderson Cancer Center and Yale University.
The FDA has granted Fast Track designation to ATR04-484 for EGFR inhibitor-associated rash, which affects approximately 150,000 patients annually in the United States.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Azitra, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →